NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma

Title
NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma
Authors
Keywords
NAP1L1, Hepatocellular carcinoma, Prognosis, Chemoresistance
Journal
Cancer Cell International
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-05
DOI
10.1186/s12935-019-0949-0

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now